by | Jun 25, 2024 | Uncategorized
CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the use of minimal residual disease testing to determine cessation of therapy in patients with multiple myeloma.The MRD2STOP trial, presented at ASCO Annual Meeting, observed multiple factors in patients...
by | Jun 24, 2024 | Uncategorized
CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the role of quadruplet induction regimens for transplant-ineligible patients with multiple myeloma.IMROZ and BENEFIT, randomized phase 3 trials presented at ASCO Annual Meeting, investigated the...
by | Jun 24, 2024 | Uncategorized
Source: CureToday articles A beautiful tapestry reminded me to stay positive, even during a challenging time with cancer. Read More
by | Jun 24, 2024 | Uncategorized
CHICAGO — In this video, Adam Cohen, MD, discussed findings from the DREAMM-7 and DREAMM-8 trials presented at ASCO Annual Meeting.The trials combined belantamab mafodotin (Blenrep, GSK) with standard-of-care treatments in patients with relapsed/refractory multiple...
by | Jun 24, 2024 | Uncategorized
Source: ASCO Daily News Drs. John Sweetenham and Marc Braunstein discuss practice-changing studies in hematologic malignancies that were featured at the 2024 ASCO Annual Meeting, including the ASC4FIRST trial in chronic myeloid leukemia and IMROZ and CARTITUDE-4 in...
by | Jun 20, 2024 | Uncategorized
Source: CureToday articles During the CURE® Educated Patient® Multiple Myeloma Summit, one expert explained the push to make CAR-T cell therapy available for patients sooner. Read More
